MitraClip Procedure Can Be Performed without General Anesthesia

Courtesy of Dr. Carlos Fava.

Avoiding general anesthesia in intervention procedures has the benefits of faster recovery and shorter hospitalization. This has been already analyzed in the context of TAVR, but not in MitraClip procedures.

Es posible realizar MitraClip sin anestesia general

The present study analyzed 232 patients receiving the MitraClip. 76 of these procedures were done under general anesthesia (32.7%) and 156 under deep sedation (67.3%).


Read also: The SOURCE 3 Confirms the Good Outcomes of the SAPIEN 3 at One Year Followup”.


Populations were similar in age, comorbidities, EuroScore, severity of mitral failure, left and right ventricular function, and renal function.

 

Both strategies saw safe MitraClip implantation, with no difference in number of implanted clips, or residual mitral failure (with low complications rate). Only 2 patients required conversion to general anesthesia. Total procedural time was lower with deep sedation (DS), driven mainly by preparation.

 

Intensive care was shorter with DS (2.6±4.4 vs. 1.5±1.4 p=0.003). However, hospital stay was similar.


Read also: New Study Confirms TAVR Durability at 5 Years”.


At 90 day follow up, both groups improved functional class and quality of life, saw reduced systolic pressure and BNP.

 

Conclusion

MitraClip implantation with DS is as safe and effective as with general anesthesia.

 

Commentary

Simplifying endovascular procedures with no quality compromise has always been beneficial.

 

Performing MitraClip procedures without general anesthesia reduced intensive care days, but with no difference in overall hospital stay. This might be because the researchers looked at patients between 2011 and 2015. After gaining experience and improving devices, this factor might improve as well. 

 

To know the kind of patients that will benefit from this strategy calls for further research.

 

Courtesy of Dr. Carlos Fava.

 

Original Title: Deep Sedation Vs. Geneal Anesthesia in 232 patients undergoing Percutaneous Mitral Valve repair using the MitraClip® System.

Reference: Patrick Horn, et al Catheterization Cardiovascular Intervention 2017 Published online.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

Coronary artery disease progression after transcatheter aortic valve replacement: quantitative coronary angiography and Quantitative Flow Ratio analysis

The coexistence of coronary artery disease and severe aortic stenosis is common among patients undergoing transcatheter aortic valve replacement (TAVR). However, the impact of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...